Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Channel Therapeutics Corp CHRO

Healthcare Biotechnology
Channel Therapeutics Corporation, formerly Chromocell Therapeutics Corporation, is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel, NaV1.7, which has been genetically validated as a pain receptor in human physiology. It operates three programs developing pain treatment therapeutics: Neuropathic Pain, Eye Pain, and Depot. It is engaged in developing, CC8464, to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 channels in the peripheral nervous system. Based on a novel formulation of CC8464, its Eye Pain program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. Based on several novel formulations of CC8464, its program, titled CT3000, is for the potential treatment of postoperative pain with the use of nerve blocks.


NYSEAM:CHRO - Post by User

Channel Therapeutics Corp
<< Previous
 Bullboard Posts
User Avatar Image
(125)
•••
Post by coolfooldumbguyon Jan 21, 2025 3:26pm
18 Views
Post# 36413965

Sold out of this stock today.

Sold out of this stock today.It was a good time for me to get out of this one.It was a big triple for me in the price per share.So that my sell order at the $3.39 cent mark was filled and that was good enough.
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities